Meeting
2014 ASCO Annual Meeting
Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer.
Authors
Otto Metzger-Filho
Dana-Farber Cancer Institute, Boston, MA
Otto Metzger-Filho , William Thomas Barry , Ian E. Krop , W. Jerry Younger , Elizabeth S Lawler , Eric P. Winer , Nancy U. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01921335
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS660)
DOI
10.1200/jco.2014.32.15_suppl.tps660
Abstract #
TPS660
Poster Bd #
120A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).
First Author: Cristiano Ferrario
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).
First Author: Haeseong Park
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
Poster
2021 Gastrointestinal Cancers Symposium
MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
First Author: John H. Strickler